Laurel Copeland to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Laurel Copeland has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
0.275
-
Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR, Fine MJ. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012 Dec; 55(11):1466-73.
Score: 0.095
-
Mortensen EM, Copeland LA, Pugh MJ, Restrepo MI, de Molina RM, Nakashima B, Anzueto A. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009 Jun 03; 10:45.
Score: 0.076
-
Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A. Association of hydrophilic versus lipophilic angiotensin-converting enzyme inhibitor use on pneumonia-related mortality. Am J Med Sci. 2008 Dec; 336(6):462-6.
Score: 0.074
-
Owen-Smith A, Stewart C, Green C, Ahmedani BK, Waitzfelder BE, Rossom R, Copeland LA, Simon GE. Adherence to common cardiovascular medications in patients with schizophrenia vs. patients without psychiatric illness. Gen Hosp Psychiatry. 2016 Jan-Feb; 38:9-14.
Score: 0.029